Pegvisomant in Acromegaly and Gigantism by Briet, Claire et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 7
Pegvisomant in Acromegaly and Gigantism
Claire Briet, Valentine Suteau and Patrice Rodien
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.91251
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
l ir   ri t, l ti   t   tric   i
Additional infor ation is available at the end of the chapter
Abstract
Pegvisomant is a GH antagonist used in acromegaly in gigantism. Pegvisomant is a 
modified GH molecule with pegylation to increase half-life and nine amino acid substi-
tutions to modify GH receptor affinity and dimerization. Pegvisomant leads to an IGF1 
decrease. It is administered subcutaneously every day with a median dose of 15 mg/
day in meta-analysis. This treatment is indicated in acromegaly or gigantism in case of 
resistance to somatostatin analogs. This drug leads to a control of acromegaly in 90% of 
patients in phase III study and about 70% of patients in real-life study. In gigantism, only 
50% of children are controlled with pegvisomant. It is a well-tolerated treatment with 
hepatic side effects in 3% of cases, headache in 2% of cases, and lipohypertrophy in 3% 
of cases. Pegvisomant does not act on adenoma size, and 6% of increasing tumour size 
is observed. Indeed, pegvisomant is an antagonist of GH receptor with a good efficacy 
which can be used alone or in association with somatostatin analog or cabergoline if 
acromegaly is not controlled by a somatostatin analog.
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1. Introduction
Pegvisomant is the only available GH antagonist. The history of pegvisomant development 
is an example of how research can be surprising. By combining site-specific mutation on the 
GH gene, researchers were looking for a long-acting GH treatment. However, researchers 
were surprised to find with the in vivo analysis an IGF1 reduction in mice treated with the 
modified GH molecule obtained. It was the beginning of pegvisomant history.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Structure-function
2.1. Development of a long-acting GH antagonist
GH three-dimensional structure contains two disulphide bridges and four helices which are 
arranged in an “up-up-down-down” topology. Helices 1, 2, 3, and 4 are located between 
residues 9–34, 72–92, 106–128, and 155–184, respectively (Figure 1) [1]. Helix 3 is the key to 
promote a growth activity. In this helix, approximately 20 amino acids are arranged in an 
amphiphilic orientation. Among them, three amino acids do not enable an ideal amphiphilic 
helix [2]. When modifying these three amino acids, researchers wanted to generate a perfect 
amphiphilic helix 3 and hypothesised that it would enhance GH activity. Surprisingly, trans-
genic mice expressing this modified GH analog had decreased circulating IGF1 concentra-
tions. It was the first report of a GH antagonist [3]. Further single amino acid substitutions 
demonstrated that glycine at position 120 of human GH was critical for the growth-promoting 
activity of the respective molecule. Crystallography studies demonstrated that this mutation 
of the glycine to a lysine at position 120 (G120K) of GH led to a defect of GHR dimerisation 
which is essential for GH transduction signal [4].
However, because of its small size (22 kDa), GH is rapidly cleared by the kidneys and/or 
endocytosis as a GH/GHR complex. Indeed, the addition of polyethylene glycol (PEG) (5 kDa) 
Figure 1. Two-dimensional representation of the structure of human GH (adapted from de Vos et al.) [4].
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increased the serum half-life from 30 min to 2 days. At this stage, we had a G120K-PEG GH 
molecule. However, the perfect GH antagonist was not yet found because the addition of 
PEG led to a decrease of binding affinity for site 1 (which is the first binding site of the GH 
molecule on the GH receptor). To circumvent this problem, mutagenesis of binding site 1 was 
considered. In the meantime, Cunningham and Wells published a more potent GH analog 
with eight amino acid substitutions in site 1 of the GH molecule. These eight mutations were 
introduced in the G120K-PEG GH molecule [5]. This molecule proved to maintain binding 
affinity for binding site 1 of GHR, antagonising properties of GHR with a long half-life. That 
was the birth of pegvisomant.
2.2. The pegvisomant/GHR interaction
Pegvisomant/GHR interaction has been more precisely studied. Primary studies suggest 
that pegvisomant binds to one GHR and prevents GHR dimerisation because of the G120K 
mutation which prevents binding to site 2. However, further studies show that pegvisomant 
Figure 2. Binding representation of GH and pegvisomant (B2036-PEG) on GH receptor and schematic effect [1]. GH 
binds to GHBP and to binding site 1 and 2, inducing a conformational change of GHR, a jak/stat phosphorylation, and 
internalisation [2]. Pegvisomant binds to GHBP, and the complex binds to site 1 and site 2, inducing a less functional 
dimerization, a diminution of jak/stat phosphorylation, and a different intracellular trafficking with an increase of GH 
receptor degradation (adapted from Ross et al.) [6].
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induces GHR dimerisation with disulphide linkage and induces internalisation, as GH do. 
However, activation of jak kinase and stat 5 is less important because the conformation changes 
after pegvisomant binding is different with a less functional dimerisation [6, 7]. Moreover, 
internalisation after pegvisomant binding induces a different intracellular trafficking, with an 
increase of degradation of GHR, a decrease of GHR expression on cellular membrane, and a 
decrease of nuclear localisation of GHR [8].
Moreover, it appears that the eight mutations within site 1 do not increase affinity to GHR 
but to the GH binding protein and allow the dimerisation of GHR despite the pegylation 
(Figure 2) [7]. Reducing site 1 binding affinity, high doses of pegvisomant are necessary to 
antagonise GH action.
3. Safety-efficacy
3.1. Phase I
In the phase I study, 36 young volunteers received a single injection of either the placebo 
or pegvisomant (0.03, 0.1, 0.3, or 1.0 mg/kg). All doses were well tolerated, with no severe 
adverse events. IGF1 decreased significantly in all groups with a pegvisomant dose above 
0.1 mg/kg (P < 0.001 vs. placebo) [9].
3.2. Phase II
In the phase II study, 46 patients with active acromegaly were randomised and received the 
placebo, 30 or 80 mg of pegvisomant once a week for 6 weeks. If IGF1 levels were unchanged 
in the placebo group, it decreased by 31 ± 6.7% in the 80 mg groups (P < 0.001). There was 
a dose-related decrease in serum IGF1. However, only three patients have a normal serum 
IGF1. Pharmacokinetic study evaluated pegvisomant half-life at 70 h [10]. Because of the low 
efficacy of pegvisomant in phase II and the half-life of 70 h, it was decided to give pegviso-
mant daily in phase III.
3.3. Phase III
The phase III study on 112 patients with acromegaly showed the efficacy of pegvisomant 
on serum IGF1 reduction and clinical improvement. This double-blind study showed 
a decrease of IGF1 from the baseline by 26.7 ± 27.9%, 50.1 ± 26.7%, and 62.5 ± 21.3% in 
the groups that received 10 mg, 15 mg, and 20 mg of pegvisomant per day, respectively 
(P < 0.001 for the comparison of each pegvisomant group with placebo). In these groups, 
54%, 81%, and 89% had a normalised IGF1 at 12 weeks. Among patients treated with 15 mg 
or 20 mg of pegvisomant per day, there were significant decreases in clinical symptoms 
such as ring size, soft tissue swelling, the degree of excessive perspiration, and fatigue. 
Quality of life improved in all groups. Tumour volume was similar before pegvisomant and 
at 12 weeks [11]. One year later, van der Lely et al. published the extension of this study, 
with 152 patients on pegvisomant at 18 months; 97% of patient normalised serum IGF1 
(Table 1) [12].
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3.4. Long-term experience
3.4.1. Efficacy
The ACROSTUDY is the largest international, noninterventional study of acromegaly patients 
treated by pegvisomant. Two thousand and ninety patients were analysed between 2004 and 
2016. When starting pegvisomant, 89% of patients had an IGF1 above the upper limit of nor-
mal (ULN), previously treated by surgery, radiotherapy, medical therapy, or a combination 
of the three. After 10 years, 73% of patients had a normal IGF1 with a median dose of pegvi-
somant 18.9 mg/day (Table 1) [13].
A recent study evaluated the efficacy in real life. A Brazilian multicentre study of 109 patients 
with acromegaly were included, 61% were women, and 95% have macroadenomas. Previous 
treatments were surgery (89%), radiotherapy (34%), somatostatin analogs (99%), and/or 
cabergoline (67%). No patients were controlled at inclusion with high IGF1 (median 209% 
of ULN) and high GH secretion. For most patients the initial dose was 10 mg/day, and the 
median exposure was 30.5 months. Pegvisomant was used as monotherapy in 11%. IGF1 nor-
malisation was obtained in 74% of patients with a median dose of 15 mg/day when used alone 
and 10 mg/day in combined therapy. In this study, there were three response predictors: 
exposure time, GH pretreatment, and IGF1 pretreatment (Table 1) [14].
In a recent meta-analysis of eight studies, 60.9% of patients were controlled (52–70; 95% CI) 
and 72% if considering only patients in monotherapy in five studies [15].
Interestingly, there are two cases of persistent remission of acromegaly after pegvisomant 
withdrawal. Patients were treated for 8 and 11 years and presented a normal IGF1 and GH 
secretion 5 and 2 years after withdrawal, respectively [16].
N 
(female)
IGF1 before 
pegvisomant 
% ULN
Median 
exposure 
time 
(months)
Median 
dose 
mg/day 
(min 
max)
Monotherapy 
(% of 
patients)
Normal 
IGF1 
(% of 
patients)
Tumour 
enlargement 
(% of 
patients)
Liver 
enzyme 
elevation 
(% of 
patients)
Boguszewski 
et al. [14]
109 (61) 209 (99–637) 30.5 10 
(10–30)
11 74.1% 6 9.2
Basavilbaso 
et al. [33]
75 (51) 240 (125–700) 27 12 (3–30) 45 63% 9.8 9.3
Buchfelder 
et al. [13]
2090 NA 91.2 18.9 NA 73 2.2 3
Van der Lely 
et al. [12]
90 NA 18 19.6 100 97 1.3 1.3
Garcia  
et al. [18]
42 NA NA NA NA 58 NA NA
Rostomyan 
et al. [19]
37 NA NA NA NA 51 NA NA
NA: not available; ULN: Upper limit normal.
Table 1. Main study of pegvisomant efficacy and adverse events in real life.
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3.4.2. Adherence
In a recent study, treatment adherence to pegvisomant was evaluated in a multicentre cross-
sectional study on patients treated with pegvisomant for more than 12 months in 108 patients. 
Rates of adherence varied from 61 to 92% and did not correlate to disease control. Older 
patients and patients with an alternative schedule had lower adherence. However, treatment 
satisfaction was high, 75 ± 15%, evaluated with the “Treatment Satisfaction with Medicines 
Questionnaire” (STATMED-Q). This study reveals that the principal obstacle was the trans-
portation of the pegvisomant (especially maintaining the cold chain during transportation) 
and anxiety about the injection. One third of patients made mistakes during the reconstitution 
(17%) and administration (22%) of pegvisomant [17].
3.5. Experience of pegvisomant in children
Experience of pegvisomant in children is quite rare. There is a recent review of the case series 
of gigantism in the literature. Out of 262 patients, 42 (17.5%) were treated with pegvisomant 
and 27 (58%) had normal IGF1 [18]. The biggest series was published in 2015 with 208 patients 
with gigantism. Among them 37 were treated with pegvisomant and 19/37 (51%) had a nor-
mal IGF1. Indeed, gigantism seems to be more difficult to control than acromegaly in adult-
hood with pegvisomant [19].
4. Indication
4.1. Acromegaly patients
Endocrine society guidelines for acromegaly were published in 2014 [20]. The first recom-
mended treatment of acromegaly is surgery, as it offers the prospect of a cure. In case of 
persistent GH secretion 12 weeks after surgery, medical treatment is indicated including 
cabergoline and long-acting somatostatin (SMS) analogs. Cabergoline is indicated in case of 
co-secretion of GH and PRL or if GH secretion is slightly increased (IGF1 < 2.5 times the upper 
normal range) and permits 40–50% of control [21, 22]. The first generation of long-acting SMS 
analog studies report around 50% of IGF1 normalisation [23]. For patients who are not con-
trolled by the first-generation SMS analogs, the recent consensus recommends several options:
Add cabergoline if IGF1 is <2.5 times the upper normal range.
Switch to pasireotide, the second-generation of SMS analogs which normalised IGF1 in up to 
54% of patients [24].
Switch or add pegvisomant [25].
Pegvisomant is indicated in cases of resistance to SMS analog in a second- or third-line therapy 
[20]. In addition, pegvisomant should be considered in patient with uncontrolled diabetes 
with partial or no response to first-line medical therapy [25].
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4.2. Posology
For the first dose, 80 mg is recommended, followed by 10 mg/day. IGF1 should be measured 
8 weeks after, and pegvisomant should be increased by stages of 5 mg.
The dose of pegvisomant required to normalise IGF1 can be evaluated with age and BMI; 
however, it is recommended to monitor IGF1 in order to adapt pegvisomant dosage. Using 
dose above 30 mg/day is not recommended [26].
4.3. Combination therapy
When patients are not controlled with somatostatin analog ± cabergoline, the question of add-
ing pegvisomant or switching to pegvisomant is not yet resolved. Initially, with serum IGF1 
normalisation in over 90% of patients with acromegaly receiving pegvisomant, the indications 
for combined therapy were limited. However, in real life, as efficacy is lower (almost 70%), 
the combination therapy is questionable. Moreover, because of the risk of tumour growth 
and chiasma compression, the strategy for macroadenoma was often to add pegvisomant to 
somatostatin analog. However, the routine use of SMS analog and pegvisomant in combina-
tion may also be prohibitively expensive [27].
A randomised trial compared the two strategies for patients uncontrolled under long-acting 
octreotide: switched to pegvisomant alone or added pegvisomant. IGF1 normalisation was 
similar in both groups (56% for pegvisomant alone and 62% for combined therapy). The ques-
tion still remains unanswered [28].
In a large Dutch cohort of patients with acromegaly treated with the association of somatosta-
tin analog and pegvisomant for 9 years, 97% of patients had a normal IGF1 with a median 
dose of pegvisomant of 80 mg/week [29].
Moreover, the association of cabergoline and pegvisomant for patients with a slightly increase 
of IGF1 under pegvisomant alone for 18 months enabled acromegaly control in four patients 
(28%) [22].
4.4. Monitoring and objectives
IGF1 is the only biological marker to evaluate disease activity on pegvisomant. As it is a GH 
antagonist, it is not recommended to follow GH secretion. Indeed, scoring systems have been 
developed to evaluate the activity of acromegaly. In this way, SAGIT and ACRODAT are 
additional tools to assess overall disease activity [30, 31]. AcroQol can be useful to evaluate 
the quality of life of acromegaly patient under treatment [32].
5. Adverse events
5.1. Hepatic
In the phase III study, one patient with 15 mg/day of pegvisomant withdrew after 8 weeks 
of therapy because of elevated serum aminotransferase levels, with a normalisation of liver 
Pegvisomant in Acromegaly and Gigantism
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function after withdrawal. In this patient, serum alanine aminotransferase and aspartate ami-
notransferase rose to 20 N and 10 N, respectively. In the cohort of patients receiving pegviso-
mant, mean serum aminotransferase levels were stable (n = 80) [11].
In the Brazilian and Argentinian cohort, elevation of liver enzymes was reported in 9% of 
cases and was responsible for pegvisomant discontinuation in 1 and 5 patients, respectively 
(Table 1) [14, 33].
A recent meta-analysis of 6 studies with pegvisomant in monotherapy showed an overall rate 
of transaminase elevation of 3.0% (1.7–5.2%; 95% CI; I 2 = 55%) (Table 1) [15].
5.2. Headache
In the phase III study, one patient with 15 mg/day of pegvisomant withdrew due to persis-
tent headaches [11]. In the Brazilian real-life study, headaches were reported in two cases 
(1.8%) [14].
5.3. Cutaneous lipohypertrophy
In the phase III study, injection site reactions were reported in six patients (5%) receiving 
pegvisomant [11]. In the Brazilian real-life study, it was reported in 4.6% of patients [14]. Pain 
from injection was reported in 2.7% patients.
In the Argentinian cohort, 3 out of 75 patients had localised lipodystrophy [33].
A recent meta-analysis of five studies with pegvisomant showed lipohypertrophy in 1.6% of 
patients (0.6–4.3%; 95% CI; I 2 = 69%) [15].
5.4. Antibody formation
Because of the nine amino acid substitutions, pegvisomant is different from GH and can be 
considered as foreign protein leading to an immunoreactivity. Pegylation of the molecule 
reduces immunogenicity. However, in the phase III study and its extension, anti-GH antibod-
ies were reported in 8/112 (7%) patients between 1:14 and 1:64 and pegvisomant antibody in 
16.9% [12, 15].
5.5. Metabolic
Several studies evaluated glucose metabolism in patients with pegvisomant. In 53 patients 
initially treated by long-acting octreotide, the switch for pegvisomant treatment induced 
normalisation of IGF1 in 78% of cases at 32 weeks and a significant diminution of median 
fasting glucose (1.4 mmol/l) and HbA1C (−0.2%) whatever the diabetes and IGF1 status. In 
the subgroup of diabetic patients, a significant decrease of HbA1C (−1%) was observed [34].
In the ACROSTUDY, among the 1762 patients, 29% had diabetes before pegvisomant. At year 
4, mean fasting blood glucose decreased from 140 ± 59 to 120 ± 44 mg/dl, and the decrease of 
HbA1C was not significant whatever the diabetes status [35].
In a recent meta-analysis, pegvisomant significantly decreased fasting blood glucose level 
(−0.8 mmol/l; 95% CI; −1.0 to −0.6), fasting insulin level (−5.31; 95% CI; −10.2 to −0.4), and 
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HbA1c (−0.43%; 95% CI; −0.6 to −0.3). Indeed, HOMA-I also decreased −0.61 (95% CI; −1.2 to 
−0.04). This increase in glucose metabolism was not correlated to IGF1 level [36].
5.6. Tumour size
In the ACROSTUDY, subjects received pegvisomant for a mean of 5.4 years, and 12 out of 542 
subjects (2.2%) had a confirmed increase in tumour size (Table 1) [37].
In the Brazilian study, tumour enlargement was reported in 6.5% of cases (n = 5). In the 
Argentinian study, 4 of 50 patients (8%) showed an increase in tumour size with pegvisomant 
(Table 1) [33]. In the meta-analysis of five studies with pegvisomant in monotherapy, the 
overall tumour growth rate was 7.2% (4.8–10.7%; 95% CI; I 2 = 0%) [15].
5.7. Bones
The bone is a well-known fragility key point in acromegaly with a high incidence of vertebral 
fractures [38]. A recent study evaluated vertebral fracture in 55 patients resistant to the first 
generation of somatostatin analogs. Before introducing pasireotide or pegvisomant, verte-
bral fracture occurred in 23 patients (42%). In uncontrolled acromegaly, there were 78% of 
vertebral fractures under pegvisomant and 25% under pasireotide (p = 0.04). In controlled 
acromegaly, there were 23% of vertebral fractures under pegvisomant and 12.5% under pasir-
eotide (p = 0.4). Indeed, vertebral fractures seem to be more frequent with pegvisomant [39].
However, another longitudinal study has a different result in 83 patients treated with soma-
tostatin analog alone (42 cases), pegvisomant alone (6 cases), or in combination with somatosta-
tin analog (35 cases) for a median period of 82 months (range 36–126). In this longitudinal study, 
the authors observed a global decrease in incidence of radiological vertebral fractures from 43.9 
to 26.8% (p = 0.039). For patients treated by pegvisomant, the incidence of vertebral fractures 
was not significantly decreased as compared to patients treated with somatostatin analog (10.0 
vs. 26.7%; p = 0.09). In this study, pegvisomant did not increase vertebral fractures [40].
6. Conclusion
Pegvisomant is an antagonist of GH receptor with a good efficacy. It can be used alone or in 
association with somatostatin analog or cabergoline if acromegaly is not controlled with soma-
tostatin analog alone. The efficacy in real life is around 75% in acromegaly and 50% for gigan-
tism. Indeed, pegvisomant can be used in the second medical stage after somatostatin analog.
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